Last updated: August 28, 2026
Chlordiazepoxide hydrochloride and clidinium bromide is a legacy fixed-dose oral capsule marketed in the United States under the Librax brand. The combination contains 5 mg of chlordiazepoxide hydrochloride and 2.5 mg of clidinium bromide per capsule. Its commercial opportunity is primarily generic substitution, supply continuity, and reformulation rather than broad market expansion.
The combination has limited modern patent protection, but commercial entry remains constrained by controlled-substance requirements, a mature prescription market, low-to-moderate demand, physician preference for newer gastrointestinal therapies, and the need to match the reference product’s capsule performance. Excipients can create meaningful differentiation through lactose reduction, capsule-shell design, dissolution control, stability, and manufacturing efficiency. They are unlikely to support broad exclusivity unless incorporated into a genuinely novel formulation with defensible technical advantages.
What is chlordiazepoxide hydrochloride and clidinium bromide used for?
Chlordiazepoxide hydrochloride and clidinium bromide is an oral anticholinergic-benzodiazepine combination used as an adjunct in the treatment of peptic ulcer disease and irritable bowel syndrome. The product has also been labeled for acute enterocolitis. Chlordiazepoxide provides anxiolytic and sedative activity, while clidinium bromide reduces gastrointestinal smooth-muscle spasm and secretions. [1]
| Attribute |
Product information |
| Active ingredients |
Chlordiazepoxide hydrochloride and clidinium bromide |
| Strength |
5 mg/2.5 mg per capsule |
| Dosage form |
Oral hard gelatin capsule |
| Reference brand |
Librax |
| FDA regulatory pathway |
Original NDA product; generic entry generally through ANDA |
| Controlled substance |
Chlordiazepoxide is a Schedule IV benzodiazepine |
| Main therapeutic area |
Gastrointestinal antispasmodic and adjunctive ulcer treatment |
| Primary commercial issue |
Mature product with limited differentiation and controlled-substance compliance |
The combination is not a biologic and has no biosimilar pathway. Competitive entry is therefore based on generic-drug approval, pharmaceutical equivalence, bioequivalence, manufacturing capability, and commercial contracting.
What excipients are used in chlordiazepoxide and clidinium bromide capsules?
The excipient profile depends on the manufacturer. Reference and generic products typically use a conventional hard-gelatin capsule platform with a compact powder fill. Common excipient categories include lactose or another diluent, starch or a disintegrant, talc or another glidant, and magnesium stearate or another lubricant. Capsule shells may contain gelatin, titanium dioxide, and permitted colorants. The exact composition must be confirmed from the current product-specific labeling and approved regulatory file. [1,2]
Core excipient functions
| Excipient category |
Commercial function |
Main development concern |
| Diluent |
Provides bulk and improves blend uniformity at low drug load |
Lactose intolerance, moisture, supplier continuity |
| Disintegrant |
Promotes capsule-plug breakup and drug release |
Overuse can affect blend flow and capsule fill |
| Glidant |
Improves powder flow into capsule bodies |
Excessive levels can slow wetting or dissolution |
| Lubricant |
Reduces tooling adhesion and ejection force |
Excessive lubrication can reduce dissolution |
| Colorant |
Supports product identification and brand continuity |
Regulatory restrictions and supply changes |
| Capsule shell |
Provides dosage-form protection and visual differentiation |
Gelatin source, brittleness, moisture transmission |
| Adsorbent or moisture-control excipient |
Protects sensitive powder blends |
Added cost and possible dissolution impact |
The low dose of each active ingredient makes content uniformity a central formulation issue. The combined fill may contain a much larger quantity of excipient than active pharmaceutical ingredient. Blend segregation, electrostatic charging, particle-size mismatch, and lubricant overmixing can produce assay variability if the process is not tightly controlled.
How should an excipient strategy be designed for this combination?
The preferred strategy is a robust immediate-release powder blend that matches the reference product’s release profile while reducing manufacturing variability. A formulation developer should prioritize the following attributes:
- Uniform distribution of both active ingredients.
- Reliable capsule-filling performance at commercial speed.
- Rapid and reproducible disintegration.
- Dissolution equivalence across the labeled shelf life.
- Low moisture uptake.
- Compatibility with hard-gelatin capsule materials.
- Simple supply-chain qualification.
- Minimal dependence on proprietary excipient grades.
Low-dose blend design
Because the active ingredients are present in milligram quantities, geometric dilution or ordered blending is likely to be more important than the selection of exotic excipients. Particle-size engineering may be more valuable than adding multiple functional excipients. A narrow particle-size distribution can reduce segregation, while a controlled preblend can improve content uniformity.
Potential design options include:
- Lactose-based direct blending for low-cost manufacture.
- Spray-dried lactose for improved flow and compressibility of the powder blend.
- Microcrystalline cellulose where a lactose-free or lower-lactose platform is commercially attractive.
- Pregelatinized starch or low-substituted hydroxypropyl cellulose for improved disintegration.
- Colloidal silicon dioxide at a controlled concentration for flow improvement.
- Sodium starch glycolate or croscarmellose sodium where rapid dispersion is required.
- Magnesium stearate at the lowest level that meets manufacturing requirements.
The selection should be driven by blend uniformity, capsule fill-weight variation, dissolution, and stability rather than by excipient novelty alone.
Lactose-free positioning
A lactose-free or reduced-lactose formulation is one of the clearest commercial opportunities. Many conventional capsules use lactose as the primary diluent because it is inexpensive, widely available, and familiar to generic manufacturers. Replacing lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a blended system could support pharmacy and prescriber differentiation.
The opportunity is limited by the size of the target population and the fact that lactose intolerance does not always require avoidance of the small lactose quantities present in solid dosage forms. A lactose-free formulation therefore has greater value as a product-selection attribute than as a basis for premium pricing.
Capsule-shell strategy
Capsule-shell design can provide practical differentiation without changing the active formulation. Options include:
- Distinctive two-tone color coding.
- Titanium-dioxide-free shell systems where permitted and commercially useful.
- Hypromellose capsules for customers seeking a non-gelatin shell.
- Improved moisture-barrier packaging for stability-sensitive fills.
- Tamper-evident packaging designed for controlled-substance distribution.
A hypromellose capsule may expand supply to customers with gelatin restrictions, but it can change moisture behavior and dissolution. The shell must be evaluated with the specific powder blend rather than treated as a direct substitute for gelatin.
What formulation patents could protect this product?
A conventional immediate-release capsule containing chlordiazepoxide hydrochloride, clidinium bromide, and standard excipients is unlikely to support strong new patent protection by itself. Broad composition-of-matter protection for these old active ingredients has expired. A new formulation patent would need to claim a specific technical arrangement that produces a non-obvious and measurable result.
Potential claim areas include:
- A defined particle-size distribution for one or both active ingredients.
- A blend architecture that prevents segregation during high-speed encapsulation.
- A specific excipient ratio that improves content uniformity.
- A moisture-protective formulation with demonstrated stability.
- A modified-release system that changes the pharmacokinetic profile.
- A capsule-shell and fill combination that improves dissolution or shelf life.
- A taste-masked or sprinkle formulation.
- A unit-dose package that materially limits moisture or accidental exposure.
Patent strength would depend on comparative data against conventional blends. A formulation patent based only on routine selection of lactose, starch, talc, or magnesium stearate would face substantial obviousness risk under U.S. patent law.
What is the patent and Orange Book status of Librax?
Librax is a legacy product. The original active-ingredient and basic combination patent term has expired. Current commercial protection is therefore more likely to depend on regulatory status, manufacturing quality, supply reliability, branding, and market access than on an active composition-of-matter patent.
The FDA Orange Book identifies patents and regulatory exclusivities relevant to approved drug products. A current Orange Book review should distinguish between:
- Active patent listings for the reference product.
- Expired historical listings.
- Method-of-use patents.
- Drug-substance or formulation patents.
- Regulatory exclusivity periods.
- Whether a generic applicant must submit a Paragraph IV certification.
For an old combination such as chlordiazepoxide hydrochloride and clidinium bromide, there is no apparent basis for a long remaining new-drug exclusivity period. Any Paragraph IV risk would depend on an actually listed and unexpired patent, not merely on the continued sale of the brand.
| Protection category |
Commercial assessment |
| Active-ingredient patent |
Expired for these legacy molecules |
| Basic fixed-dose combination protection |
Expected to be expired |
| New chemical entity exclusivity |
Expired |
| Orphan exclusivity |
Not a core protection strategy for this product |
| Pediatric exclusivity |
No evident commercial significance |
| Formulation patent |
Possible only for a technically differentiated formulation |
| Method-of-use patent |
Possible in theory, but narrow claims would be required |
| Biosimilar exclusivity |
Not applicable |
| Generic regulatory pathway |
ANDA, subject to reference-product and FDA requirements |
The relevant business conclusion is that a new entrant should not assume patent litigation will block generic competition. The more significant barriers are operational and commercial.
When does chlordiazepoxide and clidinium lose exclusivity?
The product has already passed the principal periods of U.S. small-molecule exclusivity associated with new chemical entities and original combination products. The practical loss of exclusivity occurred decades ago, not at a future scheduled date.
The remaining protection profile is best characterized as:
- No meaningful new-chemical-entity exclusivity.
- No expected biosimilar protection.
- No commercial reliance on basic active-ingredient patents.
- Potential narrow protection from later formulation or method patents.
- Regulatory dependence on an approved reference product and applicable ANDA requirements.
Patent expiration dates for historical Librax-related patents should be checked by individual patent number in USPTO Patent Center, the FDA Orange Book, and relevant family records. Patent family expiration can vary by jurisdiction, terminal disclaimers, maintenance status, and patent-term adjustments. [2,3]
Are there Paragraph IV challenges to Librax?
A Paragraph IV certification is relevant only when an ANDA applicant challenges an unexpired patent listed for the reference product. Given the age of Librax and the absence of a known commercially significant active-ingredient patent estate, Paragraph IV litigation is not expected to be the principal entry risk.
The more likely generic pathways are:
- Paragraph I certification where no patent information is listed.
- Paragraph II certification where listed patents have expired.
- Paragraph III certification where a listed patent remains unexpired but the applicant waits for expiration.
- Paragraph IV certification only if an active listed patent presents a specific challenge opportunity.
A generic applicant may still face patent disputes involving a newly approved reformulation, a later-developed delivery system, or a narrow method-of-use patent. Those disputes would not necessarily block approval of a conventional immediate-release capsule if the product avoids the protected claims.
What FDA regulatory requirements affect commercial entry?
The product is a prescription drug and includes a Schedule IV benzodiazepine component. FDA approval requirements therefore operate alongside controlled-substance obligations administered by the Drug Enforcement Administration.
Key regulatory requirements
A generic applicant should expect requirements involving:
- Pharmaceutical equivalence to the reference product.
- Bioequivalence under the applicable ANDA pathway.
- Assay and content uniformity for both active ingredients.
- Dissolution testing for the combination product.
- Stability data supporting the proposed shelf life.
- Control of degradants and impurities.
- Capsule-fill weight and blend-uniformity validation.
- Controlled-substance security and inventory controls.
- DEA registration and quota management where applicable.
- Child-resistant packaging and labeling compliance.
- Benzodiazepine dependence, abuse, sedation, and opioid-interaction warnings. [1,4]
The chlordiazepoxide component creates additional compliance exposure. Distribution records, inventory reconciliation, suspicious-order controls, theft reporting, and manufacturing-site security can increase operating costs compared with an ordinary gastrointestinal generic.
What commercial opportunities exist for excipient-led differentiation?
The highest-value opportunities are practical rather than theoretical. A company can improve the product’s economics by reducing manufacturing failures, broadening customer acceptance, or creating a product that pharmacies can source reliably.
1. Lactose-free capsule
A lactose-free product could target patients and institutions with excipient-screening requirements. The strongest commercial case would require:
- Clear lactose-free labeling.
- Stable supply of replacement diluents.
- Comparable dissolution.
- No increase in capsule size.
- Competitive cost of goods.
2. Improved content uniformity
A formulation that reduces assay variability can lower batch rejection risk and improve manufacturing yield. This is especially relevant because both active ingredients are low-dose components in a relatively large excipient matrix.
3. Hypromellose capsule
A non-gelatin capsule could support institutional and patient segments that avoid animal-derived gelatin. It may also provide a marketing distinction in a crowded generic market. The commercial value is likely modest unless supported by reliable supply and favorable purchasing contracts.
4. Moisture-protective packaging
Blister packaging, high-barrier bottles, desiccants, or unit-dose packaging can improve stability and reduce handling errors. Controlled-substance products may also benefit from packaging that supports inventory accountability.
5. Sprinkle or alternative oral dosage form
A sprinkle capsule or other administration option could serve patients with swallowing limitations. This would be a genuine formulation-development project and could require a separate regulatory strategy if the dosage form changes product performance or labeling.
6. Contract-manufacturing platform
A manufacturer that can produce multiple low-volume controlled-substance capsules under one validated platform may gain an advantage. The opportunity is based on manufacturing utilization and distribution reliability rather than on high unit margins.
How strong is the patent estate for chlordiazepoxide and clidinium bromide?
The patent estate is weak for a conventional generic capsule and potentially moderate only for a narrowly claimed, data-supported reformulation.
| Patent-estate factor |
Assessment |
| Active ingredient age |
Very old; basic protection expired |
| Combination-product protection |
Historical protection, expected expired |
| Formulation opportunity |
Available but requires technical differentiation |
| Method-of-use opportunity |
Narrow and clinically constrained |
| Biosimilar barrier |
None |
| Generic litigation exposure |
Low for a standard capsule; higher for a patented reformulation |
| Freedom-to-operate focus |
Formulation claims, manufacturing claims, packaging claims, trademarks |
| Main non-patent barrier |
Controlled-substance compliance and limited market scale |
A new entrant should conduct a claim-by-claim review of U.S. and foreign patent families covering modified release, abuse deterrence, capsule composition, manufacturing processes, and specific excipient systems. Trademark clearance is also relevant because Librax is a branded product, although generic labeling must follow applicable FDA naming and substitution rules.
Which companies are challenging the Librax market?
The market is likely to include the reference-brand sponsor, authorized or branded generic channels, and ANDA manufacturers. The exact list of active suppliers changes as approvals, discontinuations, and commercial contracts change. FDA’s Drugs@FDA and Orange Book databases are the controlling sources for approval status and listed products. [2,5]
Competition is likely to center on:
- Wholesale acquisition cost.
- Pharmacy benefit manager access.
- Product availability.
- Controlled-substance distribution capability.
- Backorder performance.
- Capsule appearance.
- Manufacturing-site reliability.
- Ability to supply both strengths or package configurations, where applicable.
Because the product is a mature combination with limited clinical growth, market share can shift quickly when one supplier experiences a manufacturing interruption.
What generic launch scenarios exist?
Standard immediate-release generic
This is the lowest-risk pathway from a patent perspective. The product must match the reference dosage form and demonstrate bioequivalence. Commercial returns may be limited by market size and generic price erosion.
Differentiated excipient generic
A lactose-free, gelatin-free, or stability-enhanced product could obtain modest price or contracting advantages. It would still face the economics of a mature generic market.
Modified-release product
A modified-release product could create new clinical and intellectual-property value, but it would require additional pharmacokinetic, clinical, and regulatory work. It would not automatically qualify as an interchangeable generic version of the immediate-release reference product.
Authorized-generic or licensing arrangement
A branded sponsor or generic manufacturer could use an authorized-generic structure to preserve supply and capture value after loss of exclusivity. The attractiveness depends on manufacturing cost, brand strategy, and distribution economics.
What licensing deals are relevant to this product?
No major recent licensing transaction is necessary to support a conventional generic launch. The most relevant deal structures would be:
- Authorized-generic licensing by the reference-product sponsor.
- Contract manufacturing for a controlled-substance capsule.
- Regional distribution licensing.
- Co-development of a lactose-free or alternative-shell product.
- Acquisition of an ANDA or approved product line.
- Supply agreements for qualified excipients and capsule shells.
A license has the strongest value where it provides regulatory assets, established controlled-substance infrastructure, pharmacy contracts, or access to a stable API supplier. A simple formulation license without regulatory or manufacturing support would have limited value because the underlying active ingredients are widely known.
What revenue exposure and market risks should investors assess?
The revenue opportunity is likely a niche generic opportunity rather than a high-growth gastrointestinal franchise. Key variables are prescription volume, net price, number of approved suppliers, product availability, and the cost of controlled-substance compliance.
Major risks include:
- Rapid price erosion after multiple generic entrants.
- Low prescription volume.
- Brand substitution and formulary exclusion.
- Clinical movement toward non-benzodiazepine therapies.
- Abuse, dependence, and opioid-related safety scrutiny.
- DEA quota or distribution constraints.
- API or capsule-shell shortages.
- Product discontinuation by low-volume manufacturers.
- Litigation over a later formulation patent.
- Reputational exposure from benzodiazepine distribution.
A differentiated excipient platform can improve supply reliability and customer retention, but it is unlikely to transform the market without a new dosage form, clinically meaningful benefit, or protected manufacturing advantage.
Key Takeaways
- Chlordiazepoxide hydrochloride and clidinium bromide is a legacy 5 mg/2.5 mg hard-gelatin capsule combination marketed as Librax.
- Basic active-ingredient and combination-product patent protection has expired.
- Biosimilar risk is irrelevant because this is a small-molecule product.
- A conventional generic capsule is primarily an ANDA and manufacturing opportunity, not a patent opportunity.
- The strongest excipient strategies are lactose reduction, improved blend uniformity, moisture control, alternative capsule shells, and manufacturing robustness.
- New formulation patents require comparative technical data and narrowly drafted claims.
- Controlled-substance compliance is a material barrier to entry.
- Commercial returns are likely to depend on supply reliability, contracting, and cost control.
- Modified-release, sprinkle, or alternative-shell products could create greater differentiation but would carry higher regulatory and development costs.
- The market is vulnerable to price erosion and may remain commercially limited despite the low patent barrier.
FAQs
Is chlordiazepoxide and clidinium bromide available as a generic drug?
Generic versions may be available depending on current FDA approval and commercial-distribution status. Availability should be confirmed in the current FDA Orange Book and Drugs@FDA records.
Can lactose be removed from a Librax generic formulation?
Yes. Lactose can be replaced with alternative diluents, but the revised formulation must meet content-uniformity, dissolution, stability, and bioequivalence requirements.
Is chlordiazepoxide and clidinium bromide a controlled substance?
The chlordiazepoxide component is a Schedule IV benzodiazepine in the United States. Manufacturing and distribution therefore require controlled-substance compliance measures.
Could a new capsule shell receive patent protection?
A capsule shell alone is unlikely to support strong protection unless it is part of a specific formulation or delivery system that produces a demonstrated technical benefit.
Is a modified-release version commercially attractive?
It could offer differentiation, but it would require substantially more development than a standard generic capsule. The product would face pharmacokinetic, regulatory, clinical, manufacturing, and patent-development costs.
References
-
U.S. Food and Drug Administration. (2024). Librax (chlordiazepoxide hydrochloride and clidinium bromide) capsule prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
United States Patent and Trademark Office. (2025). Patent Center and patent term information. U.S. Department of Commerce.
-
U.S. Drug Enforcement Administration. (2024). Controlled substances act, Schedule IV substances. U.S. Department of Justice.
-
U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs database.
